Global Acquired Autoimmune Hemolytic Anemia Market Analysis

back-icon

Back to Report

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Acquired Autoimmune Hemolytic Anemia Market Analysis

  • Pharmaceutical
  • Jan 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Hemolytic anemia is a type of anemia that occurs when your red blood cells break down or die quicker than your body can replace them with new ones. Hemolytic anemia can be caused by inheriting anemia-causing genetic disorders, infections, or specific drugs. Hemolytic anemia treatment varies based on the origin of the sickness. Blood transfusions, corticosteroid medications, and Rituximab are all possible treatments. Surgery to remove the spleen is recommended in more severe cases. Warm antibody hemolytic anemia and cold antibody hemolytic anemia are two types of acquired (autoimmune) hemolytic anemia. Autoantibodies attach to red blood cells in warm antibody hemolytic anemia and destroy them at a temperature higher than body temperature; in cold antibody hemolytic anemia, self-generated antibodies kill red blood cells at a temperature lower than body temperature.

Filled Map Analysis